GDF15 and metastatic melanoma: Previous studies in metastatic melanoma patients treated with ipilimumab have shown that elevated serum GDF-15 levels adversely affect overall survival, suggesting that this association may reflect disease characteristics rather than a direct impact on immunotherapy response [19].